
Obesity is a global epidemic, which, directly and indirectly, contributes to almost all cardiovascular diseases, including atherosclerotic cardiovascular disease, heart failure and atrial fibrillation. Reduction of weight is associated with substantial improvements in cardiometabolic risk factors, including blood pressure and glycaemic control, with over 10% weight loss required to see improvement in rates of major adverse cardiovascular events. Glucagon-like peptide-1 (GLP-1) receptor agonists have changed the landscape of type 2 diabetes and obesity management, showing significant benefit in glycaemic control and weight loss. Their potential for cardiovascular benefits means that they will likely have a central role in the management of patients with obesity-related cardiovascular diseases. This review summarises currently available GLP-1-based pharmacotherapies and highlights recent trials demonstrating cardiovascular benefits, and also provides practical guidance for patient selection, available agents, their initiation and patient monitoring. This will serve as an aid for cardiovascular clinicians, who will inevitably encounter patients suitable for, or already using, these drugs in their daily practice.
Coronary artery disease (CAD) remains a leading cause of morbidity and mortality globally, with early identification and management of risk factors being crucial to its management. Patients undergoing day-case angiograms represent a relatively high-risk population, yet often lack comprehensive risk-factor evaluation. Interventions have been shown to be more consistently aligned with guideline-recommended targets when conducted in hospital. As such, the cardiac catheterisation lab offers an invaluable opportunity for cardiovascular risk factor screening and intervention. We enrolled 585 consecutive patients attending our institution for day-case coronary angiograms. Blood samples were collected for lipid profile and glycated haemoglobin (HbA1c), in addition to blood pressure recordings and a smoking history taken. The results were available for clinician review on the day, with encouragement to intervene on off-target risk factors. We identified high levels of patients with established CAD and risk factors outside of the target range. This included 77% and 70% with low-density lipoprotein (LDL) and non-high-density lipoprotein (non-HDL) above target, respectively. There were also 19% smoking and 14% with HbA1c above target. A number of patients with CAD and previously undiagnosed risk factors were also identified, including 18 newly diagnosed with diabetes. A considerable proportion of these had interventions made on the day of their procedure. Our results demonstrate a clear benefit to risk-factor screening in the catheterisation lab, with a high number of patients found to have risk factors outside of the target range, or previously undiagnosed, and appropriate interventions were made as a result.
Rate-related left-bundle branch block (LBBB) is an uncommon conduction abnormality that can mimic ventricular tachycardia or myocardial ischaemia, and in prolonged cases may contribute to cardiomyopathy. We describe the case of a 49-year-old woman with a previous history of mitral valve annuloplasty, anomalous pulmonary vein correction, and atrial fibrillation ablation who presented with recurrent palpitations and exertional chest pain. Despite normal echocardiograms and negative investigations for ischaemia, initially; a subsequent repeat exercise-tolerance test in 2024 revealed tachycardia-induced LBBB. Tachycardia-induced LBBB may cause haemodynamic instability, chest pain ('painful LBBB syndrome'), or long-term ventricular dysfunction. Early recognition is important for avoiding misdiagnosis as ventricular tachycardia or acute coronary syndrome. Clinical management focuses on rate control, exclusion of coronary disease, and the use of implantable cardiac device therapy in refractory or cardiomyopathic cases. This case highlights the diagnostic challenges in patients with recurrent tachycardia-induced LBBB, the importance of excluding coronary artery disease, and the role of timely electrophysiology assessment to guide long-term management.
We present a patient with medication-refractory inappropriate sinus tachycardia (IST) who was hospital-bound and successfully treated with hybrid thoracoscopic ablation.